


# UPDATE ON PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS



The HSE introduced a managed access protocol (MAP) for PCSK9 inhibitors in July 2019. The aim of the MAP is to provide patients with heterozygous familial hypercholesterolaemia, or established atherosclerotic cardiovascular disease, with access to PCSK9 inhibitors. PCSK9 inhibitors are medicines to lower the levels of cholesterol in the blood, and include alirocumab and evolocumab.

To date, the HSE have approved 71 prescribers for PCSK9 inhibitors under this protocol. The mean age of the applicants is 60 years. By August 2023, 200 patients were accessing treatment with PCSK9 inhibitors each month under the High Tech Arrangement.

**September 2023**

**HSE Medicines Management Programme.**